These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9587051)

  • 21. Evaluation of the bioequivalence of zidovudine 100 mg capsules in healthy Thai male volunteers.
    Chompootaweep S; Poonsrisawat J; Xumseang P
    J Med Assoc Thai; 2006 Sep; 89 Suppl 3():S79-85. PubMed ID: 17722305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Studies on the bioequivalence of canrenone using pharmacokinetic data and clinical effects].
    Wallnöfer H; Gopold B; Schneider J
    Wien Med Wochenschr; 1987 Sep; 137(17):403-7. PubMed ID: 3687038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A bioequivalence study of two products of furosemide tablets.
    Awad R; Arafat T; Saket M; Saleh M; Gharaibeh M; Zmeili S; Sallam E; Shubair M; Qobrosi S
    Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):18-23. PubMed ID: 1551740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.
    Mignini F; Tomassoni D; Streccioni V; Traini E; Amenta F
    Clin Exp Hypertens; 2008 Feb; 30(2):95-108. PubMed ID: 18293165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
    Dong H; Xu F; Zhang Z; Tian Y; Chen Y
    J Mass Spectrom; 2006 Apr; 41(4):477-86. PubMed ID: 16541392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
    Abosehmah-Albidy AZ; York P; Wong V; Losowsky MS; Chrystyn H
    Br J Clin Pharmacol; 1997 Jul; 44(1):35-9. PubMed ID: 9241094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound.
    Langguth P; Hanafy A; Frenzel D; Grenier P; Nhamias A; Ohlig T; Vergnault G; Spahn-Langguth H
    Drug Dev Ind Pharm; 2005 Mar; 31(3):319-29. PubMed ID: 15830727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers.
    Mignini F; Streccioni V; Tomassoni D; Traini E; Amenta F
    Clin Exp Hypertens; 2007 Nov; 29(8):575-86. PubMed ID: 18058482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers.
    Lohitnavy O; Lohitnavy M; Sareekan K; Polnok S; Taytiwat P
    Biopharm Drug Dispos; 2003 Sep; 24(6):229-31. PubMed ID: 12973819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
    Dasgupta A; Tso G; Wells A
    Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults.
    Park K; Kim YS; Kwon KI; Park MS; Lee YJ; Kim KH
    Clin Ther; 2007 Jan; 29(1):154-62. PubMed ID: 17379055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Studies of biological availability. A critical assessment based on a study of spironolactone preparations].
    Rameis H; Bacher S
    Wien Med Wochenschr; 1988 Apr; 138(6-7):156-60. PubMed ID: 3394332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
    Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
    Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug treatment in the elderly: special aspects of diuretics (author's transl)].
    Mühlberg W; Platt D
    Aktuelle Gerontol; 1982 Jul; 12(4):134-8. PubMed ID: 6126136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple peaks and low bioavailability of furosemide correlate with the volume of fluid ingested.
    Molz KH; Pabst G; Dilger C; Weber W; Renner P; Jaeger H
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():194-200. PubMed ID: 1820878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 39. Spironolactone. II. Bioavailability.
    Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
    Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.